Axsome Therapeutics, Inc. (AXSM)

NASDAQ: AXSM · Real-Time Price · USD

186.18

+1.44 (0.78%)

At close: Feb 19, 2026, 4:00 PM EST

187.50

+1.32 (0.71%)

After-hours: Feb 19, 2026, 6:43 PM EST

Axsome Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Revenue	561.26	385.69	270.6	50.04	-	-
Revenue Growth (YoY)	65.83%	42.53%	440.80%	-	-	-
Cost of Revenue	45.66	33.3	26.07	4.1	-	-
Gross Profit	515.6	352.39	244.54	45.94	-	-
Selling, General & Admin	514.57	411.36	323.12	159.25	66.65	28.9
Research & Development	189.49	187.08	97.94	57.95	58.06	70.19
Amortization of Goodwill & Intangibles	6.38	6.39	6.38	4.14	-	-
Operating Expenses	710.44	604.83	427.44	221.34	124.71	99.09
Operating Income	-194.84	-252.44	-182.91	-175.4	-124.71	-99.09
Interest Expense	-7.6	-6.57	-6.45	-7.34	-5.7	-2.57
EBT Excluding Unusual Items	-202.44	-259.01	-189.36	-182.74	-130.4	-101.65
Merger & Restructuring Charges	-	-	-	-1.1	-	-
Other Unusual Items	-27.97	-28.12	-48.92	-3.3	-	-1.25
Pretax Income	-230.4	-287.13	-238.28	-187.13	-130.4	-102.9
Income Tax Expense	-0.88	0.09	0.96	-	-	-
Net Income	-229.53	-287.22	-239.24	-187.13	-130.4	-102.9
Net Income to Common	-229.53	-287.22	-239.24	-187.13	-130.4	-102.9
Shares Outstanding (Basic)	49	48	45	41	38	37
Shares Outstanding (Diluted)	49	48	45	41	38	37
Shares Change (YoY)	3.38%	5.48%	11.73%	8.07%	1.11%	9.37%
EPS (Basic)	-4.66	-5.99	-5.27	-4.60	-3.47	-2.77
EPS (Diluted)	-4.66	-5.99	-5.27	-4.60	-3.47	-2.77
Free Cash Flow	-101.39	-128.68	-145.66	-117.21	-108.53	-78.5
Free Cash Flow Per Share	-2.06	-2.69	-3.21	-2.88	-2.88	-2.11
Gross Margin	91.86%	91.36%	90.37%	91.81%	-	-
Operating Margin	-34.72%	-65.45%	-67.59%	-350.54%	-	-
Profit Margin	-40.89%	-74.47%	-88.41%	-373.99%	-	-
Free Cash Flow Margin	-18.07%	-33.36%	-53.83%	-234.25%	-	-
EBITDA	-187.95	-245.51	-176.07	-171	-124.63	-99.06
EBITDA Margin	-33.49%	-63.65%	-65.07%	-	-	-
D&A For EBITDA	6.89	6.92	6.83	4.4	0.08	0.02
EBIT	-194.84	-252.44	-182.91	-175.4	-124.71	-99.09
EBIT Margin	-34.72%	-65.45%	-67.59%	-	-	-
Revenue as Reported	561.26	385.69	270.6	50.04	-	-
Advertising Expenses	-	101.2	100.3	35.3	-	-

Updated Nov 3, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q